primaquine has been researched along with A-Thalassemia in 1 studies
Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Single low-dose primaquine (SLDPQ) effectively blocks the transmission of Plasmodium falciparum malaria, but anxiety remains regarding its haemolytic potential in patients with glucose-6-phopshate dehydrogenase (G6PD) deficiency." | 9.69 | Factors affecting haemoglobin dynamics in African children with acute uncomplicated Plasmodium falciparum malaria treated with single low-dose primaquine or placebo. ( Bamisaiye, A; Basara, BB; Baseke, J; Day, NPJ; Fanello, C; Kayembe, DK; Maitland, K; Muhindo, R; Mukaka, M; Namayanja, C; Ndjowo, PO; Okalebo, CB; Olupot-Olupot, P; Onyamboko, MA; Onyas, P; Taya, C; Taylor, WRJ; Titin, H; Uyoga, S; Were, W; Williams, TN, 2023) |
| "Single low-dose primaquine (SLDPQ) effectively blocks the transmission of Plasmodium falciparum malaria, but anxiety remains regarding its haemolytic potential in patients with glucose-6-phopshate dehydrogenase (G6PD) deficiency." | 5.69 | Factors affecting haemoglobin dynamics in African children with acute uncomplicated Plasmodium falciparum malaria treated with single low-dose primaquine or placebo. ( Bamisaiye, A; Basara, BB; Baseke, J; Day, NPJ; Fanello, C; Kayembe, DK; Maitland, K; Muhindo, R; Mukaka, M; Namayanja, C; Ndjowo, PO; Okalebo, CB; Olupot-Olupot, P; Onyamboko, MA; Onyas, P; Taya, C; Taylor, WRJ; Titin, H; Uyoga, S; Were, W; Williams, TN, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Onyamboko, MA | 1 |
| Olupot-Olupot, P | 1 |
| Were, W | 1 |
| Namayanja, C | 1 |
| Onyas, P | 1 |
| Titin, H | 1 |
| Baseke, J | 1 |
| Muhindo, R | 1 |
| Kayembe, DK | 1 |
| Ndjowo, PO | 1 |
| Basara, BB | 1 |
| Okalebo, CB | 1 |
| Williams, TN | 1 |
| Uyoga, S | 1 |
| Taya, C | 1 |
| Bamisaiye, A | 1 |
| Fanello, C | 1 |
| Maitland, K | 1 |
| Day, NPJ | 1 |
| Taylor, WRJ | 1 |
| Mukaka, M | 1 |
1 trial available for primaquine and A-Thalassemia
| Article | Year |
|---|---|
Factors affecting haemoglobin dynamics in African children with acute uncomplicated Plasmodium falciparum malaria treated with single low-dose primaquine or placebo.
Topics: alpha-Thalassemia; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Chil | 2023 |